Trials / Unknown
UnknownNCT01513603
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
Phase II Trial of CLAG-M in Relapsed ALL
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- New York Medical College · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.
Detailed description
Patients will receive standard dose CLAG-M (cladribine, cytarabine, mitoxantrone, filgrastim). Standard support care will be given. Efficacy will be assessed through bone marrow examinations and blood tests.
Conditions
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Burkitts Leukemia/Lymphoma
- Chronic Myelogenous Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CLAG-M | IV times 5 days |
| DRUG | CLAG-M | Chemotherapy |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2012-01-20
- Last updated
- 2012-01-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01513603. Inclusion in this directory is not an endorsement.